Fernandez-Martinez A, Tanioka M, Ahn SG, Zagami P, et al. Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC). Ann Oncol 2024 Dec 18:S0923-7534(24)04989-5. doi: 10.1016/j.annonc.2024.
PMID: 39706338